ESR1 and breast cancer: Subgroup analysis demonstrated that neratinib gave greater benefit to patients with HR+ breast cancer than to those with HR− breast cancer, suggesting that there might be a preferential effect of TKIs on targeting the interaction of ER and HER2 than does the continuation of trastuzumab with endocrine treatment (Chan et al. 2016).